Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg for 4 weeks, then increased in 2.5 mg increments to a target dose of 5-15 mg based on glycemic control and tolerability
Do not leave the bottle in direct sunlight, near a window, or under bright artificial light
Focused on short-term, localized injection studies
Low blood sugar (hypoglycemia): Symptoms may include headache, hunger, weakness, sweating, confusion, irritability, dizziness, fast heart rate, or feeling jittery
10.1016/j.ultrasmedbio.2021.04.024 Summary Keywords arrhythmia, astragaloside IV, traditional Chinese medicine, Astragalus membranaceus , pharmacological mechanisms Citation Chen M, Fu B, Zhou H and Wu Q (2025) Therapeutic potential and mechanistic insights of astragaloside IV in the treatment of arrhythmia: a comprehensive review
Actionable next steps for researchers: Define the primary biological endpoint before selecting a formulation